Objectives: The Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors.
Introduction
Stenotrophomonas maltophilia (SM) is a ubiquitous MDR Gramnegative bacillus and opportunistic pathogen. Risk factors for infection include malignancy, neutropenia, HIV, cystic fibrosis, mechanical ventilation, ICU admission, long-term central venous catheter use, recent surgery, trauma and prior broad-spectrum antibiotic administration. Common SM infections are pneumonia and bacteraemia, with reported mortality of 18% -69%. 1 The incidence of SM infections ranges from 7.1 to 14.1 per 10 000 inpatients and is increasing, with intrinsic or acquired antibiotic resistance presenting great therapeutic challenges in severe infection. 2, 3 Trimethoprim/sulfamethoxazole and ticarcillin/clavulanic acid (no longer manufactured in the USA) are first-and second-line treatments for serious SM infections, but recent studies have found in vitro resistance to these agents to be as high as 30% and 41%, respectively. 4, 5 Clinical data regarding optimal therapy for SM infection are limited. Moreover, in vitro antimicrobial susceptibility testing results may not correctly predict SM clinical treatment response with reported discrepancies among testing methods (e.g. Etest, disc diffusion versus agar dilution) and differing guidelines (e.g. EUCAST versus CLSI). Consequently, SM MIC results vary according to the conditions and methods implemented. 3 There is a great need to # The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com identify innovative treatment strategies for SM infection and a consistent antimicrobial susceptibility scheme to guide such therapy. Macrolides are never recommended for SM therapy based on high MIC values in standard assays. However, recent studies have indicated that conventional antimicrobial susceptibility testing conditions may overlook macrolide activity and antibiotic synergies against other MDR Gram-negative bacteria including Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. 6, 7 Here, we examine the potential of the commonly prescribed macrolide azithromycin to combat SM under more physiological medium conditions, in synergy with colistin or endogenous host defence factors (cathelicidin LL-37 and neutrophils) in vitro, and in vivo using a murine pneumonia model. 
Materials and methods

MIC, chequerboard and time -kill assays
Broth microdilution antimicrobial susceptibility testing was performed in CA-MHB according to CLSI guidelines and in RPMI+10%LB. Chequerboard panels were likewise performed in both media. 8, 9 Synergy, indifference and antagonism were defined by the fractional inhibitory concentration index (FICI): FICI ≤ 0.5 ¼ synergy, FICI . 0.5 to ≤4 ¼ indifference and FICI .4 ¼ antagonism. Time -kill assays were performed in CA-MHB and RPMI +10%LB as previously described, with bactericidal activity defined as a reduction in viable bacteria by ≥3 log 10 cfu/mL; synergy, ≥2 log 10 cfu/mL reduction; indifference, ,2 log 10 cfu/mL reduction; and antagonism, .2 log 10 cfu/mL increase. 10 
Fluorescence microscopy
Fluorescence microscopy was performed as previously described with the following modifications. 11 For ready visualization, SM was used at a 2 log 10 cfu/mL higher concentration than in MIC testing, along with higher, but pharmacologically achievable, concentrations of antibiotics [NBD-tagged azithromycin (20× MIC), colistin (8× 1/4 MIC) and LL-37 (10× 1/4 MIC)].
12 Bacteria were labelled with 1 mg/mL FM4-64 (membrane) and 2 mg/mL DAPI (nucleic acid) (Molecular Probes) prior to transfer onto a 1.2% agarose pad containing 20% LB broth for microscopy and image analysis using ImageJ software v1.48f and CellProfiler 2.0.
Neutrophil killing assays
Human neutrophils were isolated from healthy donors using the PolymorphPrep system (Axis-Shield) under protocols approved by the UCSD Human Subjects Institutional Review Board for use in established bacterial killing assays with minor modifications. 13 Neutrophils were resuspended in RPMI to 2×10 6 cells/mL, stimulated with 25 nM phorbol-12-myristate-13-acetate for 2 h at 378C, washed and used to seed a 96-well plate (2×10 5 cells/well). Cells were infected at an moi equal to 50 with SM that were untreated or exposed overnight to a sub-bacteriostatic concentration (0.03 mg/L) of azithromycin.
Murine pneumonia model
Adapting a published pneumonia model, A/J mice (8 -10 weeks old, Jackson Laboratory) were infected intratracheally with 2×10 6 cfu (low inoculum) or 2×10 7 cfu (high inoculum) of SM (K279a) and treated with PBS control or 50 mg/kg azithromycin subcutaneously (sc) every 24 h for one dose (low inoculum) or two doses (high inoculum).
14 Animals were euthanized and lungs harvested, weighed, homogenized, serially diluted and plated onto LB agar to enumerate cfu after 24 h of incubation at 378C. In a subset of mice infected at the high inoculum, bronchoalveolar lavage fluid (BALF) was collected at 48 h by exposing the trachea, injecting 0.8 mL of cold PBS and retrieving BALF using an 18 gauge needle connected to a 1 mL syringe. BALF was centrifuged at 500 g for 10 min and supernatants frozen at 2808C for later cytokine analysis using commercial ELISA kits for IL-1b (R&D Systems) and macrophage inflammatory protein 2 (MIP-2) (BD Biosciences). Pelleted BALF cells were resuspended in 0.25 mL cold PBS and enumerated utilizing a haemocytometer, light microscopy and Wright -Giemsa staining to determine the differential leucocyte count. Excised lungs from four mice in each group were fixed using 4% formalin, embedded in paraffin, sectioned and stained with haematoxylin -eosin for blinded analysis by a pathologist. A graded scale of 0 (absent) to 3 (extensive) was used to assess overall airspace involvement, perivascular/peribronchial inflammation, evidence of inflammation and oedema/debris or macrophages in the intra-alveolar space. All procedures were performed by a protocol approved by the UCSD Institutional Animal Care and Use Committee.
Statistics
Statistical analyses were performed using GraphPad Prism 6.0f (GraphPad Software). One-way ANOVA, two-way ANOVA or unpaired Student's t-test were utilized where appropriate. P values ,0.05 were regarded to be statistically significant.
Supplementary methods
Supplementary methods (growth curve analysis, electron microscopy, neutrophil extracellular trap and oxidative burst studies) are available as Supplementary data at JAC Online.
Results
Markedly increased activity of azithromycin against SM in tissue culture medium versus bacteriological medium Azithromycin MICs for several MDR SM strains were determined by CLSI broth microdilution methodology using either the recommended bacteriological medium, CA-MHB, or the common mammalian tissue culture medium RPMI supplemented with 10% LB broth to support equivalent bacterial growth ( Figure S1 ). A .500-fold reduction in MIC (≤0.25 versus ≥128 mg/L) was observed for nearly all isolates tested with RPMI + 10%LB compared with CA-MHB (Table 1) . Transmission electron microscopy of SM K279a cells treated with azithromycin, a ribosomal protein synthesis inhibitor, in RPMI+ 10%LB revealed ribosomal clustering consistent with its known target of action ( Figure S2 ). In a kinetic killing assay, 0.25 mg/L azithromycin had no effect on SM K279a growth in CA-MHB, but reduced bacterial cfu below detectable levels within 24 h in RPMI +10%LB (Figure 1a) .
Cationic peptides potentiate the bactericidal activity of azithromycin against SM by increasing drug entry
We recently observed synergy of azithromycin with cationic antimicrobial peptides against other Gram-negative bacilli. 7 The cationic peptide antibiotic colistin, a drug of last resort for certain MDR pathogens, is bacteriostatic against SM in RPMI+ 10%LB, but not in CA-MHB (Figure 1a) . At 1/4 MIC of both drugs, azithromycin showed potent bactericidal synergy with colistin in RPMI+ 10%LB, but not CA-MHB (Figure 1b) . The human cathelicidin LL-37 is a cationic endogenous host defence peptide abundantly produced by neutrophils and epithelial cells. Once again, at 1/4 MIC of each agent, azithromycin showed bactericidal synergy with LL-37 in RPMI + 10%LB, but not CA-MHB (Figure 1c) . Using fluorescence microscopy-based bacterial cytological profiling, both colistin and LL-37, which are known to form pores and disrupt bacterial membranes, markedly enhanced entry of fluorescently labelled (NBD-tagged) azithromycin into bacterial cells (Figure 2a and b) , facilitating azithromycin access to the 50S ribosomal subunit.
Azithromycin sensitizes SM to neutrophil killing and increases SM clearance in vivo
Azithromycin synergizes with LL-37 against SM, suggesting it could sensitize the opportunistic pathogen to killing by neutrophils, which produce the defence peptide as part of their antimicrobial arsenal. SM induced oxidative burst and the formation of neutrophil extracellular traps (in which LL-37 is deployed) from freshly isolated human neutrophils ( Figure S3 ). Overnight pretreatment of SM with a sub-bacteriostatic concentration of azithromycin sensitized the bacterium to human neutrophil killing (Figure 3a) . We next assessed the efficacy of azithromycin monotherapy in an adapted murine model of SM pneumonia, using immune susceptible A/J mice that have functional C5 complement deficiency. Under the experimental conditions, azithromycin treatment did not affect the acute histopathological features of inflammatory pneumonia (Figure 3b and Figure S4A ), the amount or composition of BALF leucocyte infiltration (Figure 3c ) nor BALF levels of pro-inflammatory cytokines MIP-2 or IL-1b ( Figure S4B ) at 48 h post-infection. However, the recovered cfu of SM from the lungs was markedly reduced by 58% in azithromycin-treated mice (1629+123 cfu/g) versus PBS controls (3898+1154 cfu/g) at 24 h in a lower inoculum challenge and reduced by 95% in azithromycin-treated mice (824+184 cfu/g) versus PBS controls (17 915+11 186 cfu/g) at 48 h in a higher inoculum challenge (Figure 3d ).
Discussion
Using SM K279a, a strain with several genes conferring resistance to heavy metals and antimicrobials (including nine resistancenodulation-division-type efflux pump genes), and several contemporary clinical SM isolates, this study demonstrated a striking difference of azithromycin potency in standard bacteriological testing medium (negligible activity, MIC as high as 256 mg/L) compared with mammalian tissue culture medium (MIC ≤0.25 mg/L) supplemented with 10% LB broth. 15 While there is no current clinical MIC breakpoint of azithromycin for SM, the EUCAST breakpoint used for the Gram-negative bacillus Campylobacter jejuni is 4 mg/L. Azithromycin also showed potent synergy with colistin, an antibiotic of last resort for MDR Gram-negative bacilli infections, and LL-37, an endogenous cationic antimicrobial peptide. As disruptors of bacterial membranes, colistin and LL-37 potentiate azithromycin entry into bacterial cells and enhance azithromycin access to its ribosomal target.
Recent studies suggest different antibiotics may work in concert or at odds with our innate immune system in the setting of infection. 13, 16 However, our understanding of the interactions between common antibiotics prescribed in clinical practice and endogenous antimicrobials such as LL-37 and the cells that produce them (e.g. neutrophils) remains limited. Whereas SM was impervious to human neutrophil killing in our ex vivo assay, it was sensitized to neutrophil killing by azithromycin pretreatment. Moreover, azithromycin showed the ability to significantly reduce SM bacterial counts in an in vivo murine pneumonia challenge model in which a predominantly neutrophilic inflammatory infiltrate was elicited in the lungs.
Traditional SM antimicrobial susceptibility testing can be problematic given inconsistencies between the results of different methods, the lack of a gold standard or universal reference method and the inability of testing results to reliably and appropriately translate to clinical efficacy. Conventional in vitro studies also inadequately account for the dynamic interactions between conventional antibiotics and the host immune response. Our study and others suggest that current standardized susceptibility testing in bacteriological medium may fail to adequately detect the bactericidal activity of azithromycin and its interactions with the innate immune system against various MDR Gram-negative bacilli, including SM. 6, 7 Limitations of our study include the modest number of SM isolates tested and the reliance on a murine pneumonia model for in vivo azithromycin activity against SM without human clinical data. Nevertheless, this preliminary investigation highlights a potential utility of azithromycin, a safe and established antibiotic, used alone or in combination with colistin, in SM infection. The work also emphasizes the importance of accounting for the dynamic interaction between conventional antibiotics and host immunity in the setting of infection. Future randomized clinical trials in humans with azithromycin will be required to determine the true utility of this finding.
